Evidence map›Paper›PMID 30176494›Full record

ArticleJournal of affective disorders2019

Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?

Jeffrey R Vittengl, Lee Anna Clark, Jasper A J Smits, Michael E Thase, Robin B Jarrett

Abstract read
In one paragraph

Article in Journal of affective disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Jeffrey R VittenglDepartment of Psychology, Truman State University, Kirksville, MO, USA. Electronic address: vittengl@truman.edu.
Lee Anna ClarkDepartment of Psychology, University of Notre Dame, Notre Dame, IN, USA.
Jasper A J SmitsDepartment of Psychology, University of Texas at Austin, Asutin, TX, USA.
Michael E ThaseDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Robin B JarrettDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: Robin.Jarrett@UTSouthwestern.edu.
Southwestern Medical Center · USThe University of Texas at Austin · USTruman State University · USUniversity of Notre Dame · USUniversity of Pennsylvania · US

Funding

PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058397 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2000 to 2011
$4.1M
PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058356 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THASE, MICHAEL E · 2000 to 2010
$3.5M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069619 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2004 to 2009
$1.7M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069618 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, EDWARD S. · 2004 to 2008
$1.5M
Cognitive Therapy for High Risk &Refractory DepressionK24MH001571 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2005 to 2009
$625k
COGNITIVE THERAPY FOR HIGH RISK &REFRACTORY DEPRESSIONK02MH001571 · NIMH · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI JARRETT, ROBIN B · 1999 to 2003
$458k
NIMH NIH HHS K02 MH001571NIMH NIH HHS K24 MH001571NIMH NIH HHS R01 MH058356NIMH NIH HHS R01 MH058397NIMH NIH HHS R01 MH069618NIMH NIH HHS R01 MH069619
6 · The paper itself

Abstract

backgroundCognitive therapy (CT) improves symptoms in adults with major depressive disorder (MDD) plus comorbid anxiety disorder, but the specific type of anxiety may influence outcomes. This study compared CT outcomes among adults with MDD plus social, other, or no comorbid anxiety disorders.

methodsOutpatients with recurrent MDD (N = 523, including 87 with social and 110 with other comorbid anxiety disorders) received acute-phase CT. Higher risk responders (n = 241 with partial or unstable response) were randomized to 8 months of continuation treatment (CT or clinical management plus fluoxetine or pill placebo), followed by 24 months of assessment. Lower risk responders (n = 49) were assessed for 32 months without additional research treatment. Depression, anxiety symptoms, and social avoidance were measured repeatedly.

resultsOther (non-social), but not social, anxiety disorders predicted elevated depression and anxiety symptoms throughout and after acute-phase CT. Social, but not other, anxiety disorder predicted greater reduction in depressive symptoms during acute-phase CT and elevated social avoidance during and after acute-phase CT. LIMITATIONS: Anxiety disorders were assessed only before acute-phase treatment. The anxiety symptom measure was brief. Generalization to other patient populations and treatments is unknown.

conclusionsNon-social comorbid anxiety disorders may reduce the efficacy of acute-phase CT for MDD by diminishing both short- and longer term outcomes relative to depressed patients without comorbid anxiety disorders. Comorbid social anxiety disorder may increase relative reductions in depressive symptoms during acute-phase CT for MDD, but patients with comorbid social anxiety disorder may require specialized focus on social avoidance during CT.

Indexed as

Cognitive Behavioral TherapyAdultAntidepressive Agents, Second-GenerationComorbidityFemaleFluoxetineHumansMajor Depressive DisorderMaleMiddle AgedPhobia, SocialRecurrenceRisk AssessmentSocial BehaviorAntidepressive Agents, Second-GenerationFluoxetineAnxiety disordersCognitive therapyComorbidityFluoxetineMajor depressive disorderSocial anxiety disorder

Identifiers

PMID30176494
PMCPMC6151272
OpenAlexW2888307708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.